Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.35 -0.1%	$18.91	$14.40 ▼ $47.00	$1.35B	1.39	895,300 shs	477,438 shs
MNKD MannKind	$4.12 -2.4%	$4.75	$4.05 ▼ $7.63	$1.25B	1.14	2.38 million shs	2.03 million shs
NVAX Novavax	$7.25 -0.5%	$6.62	$5.01 ▼ $23.86	$1.17B	3.21	7.29 million shs	5.57 million shs
VSTM Verastem	$8.31 +11.1%	$6.49	$2.10 ▼ $8.45	$456.63M	0.85	1.16 million shs	5.30 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.10%	-0.49%	+4.73%	-9.39%	-46.59%
MNKD MannKind	-2.37%	-5.72%	-10.82%	-28.53%	-14.52%
NVAX Novavax	-0.55%	+7.73%	-3.13%	-9.26%	-53.82%
VSTM Verastem	+11.10%	+9.49%	+15.82%	+46.30%	-30.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.969 of 5 stars	4.5	0.0	0.0	3.7	0.0	0.0
MNKD MannKind	2.9693 of 5 stars	3.6	1.0	0.0	3.4	1.7	1.9
NVAX Novavax	3.7192 of 5 stars	3.2	1.0	4.7	3.8	0.8	0.6
VSTM Verastem	3.0956 of 5 stars	4.5	1.0	0.0	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	164.86% Upside
MNKD MannKind	3.25	Buy	$10.00	142.72% Upside
NVAX Novavax	2.43	Hold	$19.00	162.07% Upside
VSTM Verastem	3.00	Buy	$14.33	72.48% Upside

Current Analyst Ratings Breakdown

Latest VSTM, CLDX, MNKD, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	178.72	N/A	N/A	$9.08 per share	2.24
MNKD MannKind	$297.60M	4.21	N/A	N/A	($0.91) per share	-4.53
NVAX Novavax	$1.21B	0.97	N/A	N/A	($6.04) per share	-1.20
VSTM Verastem	$10M	45.66	N/A	N/A	$2.27 per share	3.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	N/A
MNKD MannKind	-$11.94M	$0.10	58.86	17.91	N/A	8.07%	-17.74%	8.68%	8/6/2025 (Estimated)
NVAX Novavax	-$545.06M	$2.65	N/A	90.63	2.85	-32.18%	N/A	-17.05%	N/A
VSTM Verastem	-$87.37M	-$3.20	N/A	N/A	N/A	N/A	-332.73%	-73.97%	N/A

Latest VSTM, CLDX, MNKD, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
2/27/2025	Q4 2024	CLDX Celldex Therapeutics	-$0.73	-$0.71	+$0.02	-$0.71	$1.25 million	$1.18 million
2/27/2025	Q4 2024	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/26/2025	Q4 2024	MNKD MannKind	$0.03	$0.03	N/A	$0.03	$74.99 million	$76.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
MNKD MannKind	N/A	4.54	4.17
NVAX Novavax	N/A	0.93	0.93
VSTM Verastem	2.77	3.23	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
MNKD MannKind	49.55%
NVAX Novavax	53.04%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
MNKD MannKind	2.70%
NVAX Novavax	1.00%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
MNKD MannKind	400	303.93 million	267.51 million	Optionable
NVAX Novavax	1,990	161.97 million	158.58 million	Optionable
VSTM Verastem	50	54.95 million	43.53 million	Optionable

VSTM, CLDX, MNKD, and NVAX Headlines

Recent News About These Companies

Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges

May 23 at 5:49 PM | investing.com

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...

May 23 at 5:49 PM | finance.yahoo.com

Verastem expands ambitions with strong pancreatic cancer data at ASCO

May 23 at 5:49 PM | thepharmaletter.com

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

May 23 at 5:49 PM | finance.yahoo.com

Verastem Announces Positive RAMP 205 Trial Results

May 23 at 7:50 AM | tipranks.com

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22 at 5:01 PM | businesswire.com

Soleus Capital Management L.P. Reduces Stock Position in Verastem, Inc. (NASDAQ:VSTM)

May 21 at 8:13 AM | marketbeat.com

Insider Selling: Verastem, Inc. (NASDAQ:VSTM) CFO Sells 11,143 Shares of Stock

May 21 at 6:44 AM | insidertrades.com

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025 | businesswire.com

Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Takes $187,000 Position in Verastem, Inc. (NASDAQ:VSTM)

May 16, 2025 | marketbeat.com

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 177,855 Shares of Verastem, Inc. (NASDAQ:VSTM)

May 15, 2025 | marketbeat.com

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025 | businesswire.com

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

May 12, 2025 | pmlive.com

Verastem (NASDAQ:VSTM) Given New $14.00 Price Target at HC Wainwright

May 11, 2025 | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Brokerages

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Makes New $20.40 Million Investment in Verastem, Inc. (NASDAQ:VSTM)

May 10, 2025 | marketbeat.com

FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 9, 2025 | pharmexec.com

High-graded low-grade ovarian duo wins for Verastem at FDA

May 9, 2025 | bioworld.com

Verastem Oncology Cancer Drug Combination Gets FDA Approval

May 9, 2025 | marketwatch.com

Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer

May 9, 2025 | fiercepharma.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, CLDX, MNKD, and NVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.35 -0.02 (-0.10%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$20.34 -0.01 (-0.02%)

As of 05/23/2025 05:16 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

MannKind NASDAQ:MNKD

$4.12 -0.10 (-2.37%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.03 (+0.73%)

As of 05/23/2025 06:41 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Novavax NASDAQ:NVAX

$7.25 -0.04 (-0.55%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$7.20 -0.05 (-0.69%)

As of 05/23/2025 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Verastem NASDAQ:VSTM

$8.31 +0.83 (+11.10%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$8.24 -0.07 (-0.78%)

As of 05/23/2025 07:58 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time